PDS Biotechnology (PDSB) Competitors

$1.14 +0.12 (+11.17%)

As of 03:25 PM Eastern

PDSB vs. EDIT, ALEC, CHRS, CNTN, and HELP

Should you buy PDS Biotechnology stock or one of its competitors? MarketBeat compares PDS Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PDS Biotechnology include Editas Medicine (EDIT), Alector (ALEC), Coherus Oncology (CHRS), Hillstream Biopharma (CNTN), and Cybin (HELP). These companies are all part of the "pharmaceutical products" industry.

How does PDS Biotechnology compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PDS Biotechnology has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.48	-$160.06M	-$1.23	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

In the previous week, PDS Biotechnology had 7 more articles in the media than Editas Medicine. MarketBeat recorded 9 mentions for PDS Biotechnology and 2 mentions for Editas Medicine. PDS Biotechnology's average media sentiment score of 0.67 beat Editas Medicine's score of 0.65 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PDS Biotechnology has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. PDS Biotechnology's return on equity of -346.02% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
PDS Biotechnology	N/A	-346.02%	-102.36%

Editas Medicine presently has a consensus price target of $5.40, suggesting a potential upside of 101.42%. PDS Biotechnology has a consensus price target of $9.00, suggesting a potential upside of 679.22%. Given PDS Biotechnology's higher probable upside, analysts plainly believe PDS Biotechnology is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Editas Medicine has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

Summary

PDS Biotechnology beats Editas Medicine on 9 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Alector?

Alector (NASDAQ:ALEC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Alector presently has a consensus target price of $3.63, suggesting a potential upside of 64.77%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 679.22%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, PDS Biotechnology had 9 more articles in the media than Alector. MarketBeat recorded 9 mentions for PDS Biotechnology and 0 mentions for Alector. PDS Biotechnology's average media sentiment score of 0.67 beat Alector's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Alector	Neutral
PDS Biotechnology	Positive

Alector has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

PDS Biotechnology has a net margin of 0.00% compared to Alector's net margin of -680.83%. Alector's return on equity of -295.17% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
PDS Biotechnology	N/A	-346.02%	-102.36%

PDS Biotechnology has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	11.60	-$142.93M	-$1.19	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

85.8% of Alector shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 8.3% of Alector shares are owned by insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

PDS Biotechnology beats Alector on 10 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Coherus Oncology?

PDS Biotechnology (NASDAQ:PDSB) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Coherus Oncology has higher revenue and earnings than PDS Biotechnology. PDS Biotechnology is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Coherus Oncology	$42.17M	5.83	$168.02M	$1.67	0.96

PDS Biotechnology presently has a consensus price target of $9.00, suggesting a potential upside of 679.22%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 443.36%. Given PDS Biotechnology's higher probable upside, research analysts clearly believe PDS Biotechnology is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, PDS Biotechnology had 9 more articles in the media than Coherus Oncology. MarketBeat recorded 9 mentions for PDS Biotechnology and 0 mentions for Coherus Oncology. PDS Biotechnology's average media sentiment score of 0.67 beat Coherus Oncology's score of 0.33 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Positive
Coherus Oncology	Neutral

PDS Biotechnology has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Coherus Oncology has a net margin of 397.30% compared to PDS Biotechnology's net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Coherus Oncology	397.30%	-198.90%	-46.65%

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Coherus Oncology beats PDS Biotechnology on 10 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Hillstream Biopharma?

PDS Biotechnology (NASDAQ:PDSB) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by insiders. Comparatively, 6.7% of Hillstream Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PDS Biotechnology has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Hillstream Biopharma's return on equity of -31.50% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Hillstream Biopharma	N/A	-31.50%	-24.72%

PDS Biotechnology is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.97	N/A

PDS Biotechnology presently has a consensus target price of $9.00, indicating a potential upside of 679.22%. Given PDS Biotechnology's stronger consensus rating and higher probable upside, research analysts plainly believe PDS Biotechnology is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, PDS Biotechnology had 4 more articles in the media than Hillstream Biopharma. MarketBeat recorded 9 mentions for PDS Biotechnology and 5 mentions for Hillstream Biopharma. PDS Biotechnology's average media sentiment score of 0.67 beat Hillstream Biopharma's score of -0.14 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PDS Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PDS Biotechnology beats Hillstream Biopharma on 10 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to Cybin?

Cybin (NASDAQ:HELP) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, PDS Biotechnology had 9 more articles in the media than Cybin. MarketBeat recorded 9 mentions for PDS Biotechnology and 0 mentions for Cybin. PDS Biotechnology's average media sentiment score of 0.67 beat Cybin's score of 0.00 indicating that PDS Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cybin	Neutral
PDS Biotechnology	Positive

17.9% of Cybin shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cybin has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market.

Cybin's return on equity of -59.98% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-59.98%	-50.80%
PDS Biotechnology	N/A	-346.02%	-102.36%

Cybin presently has a consensus target price of $58.75, indicating a potential upside of 1,170.27%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 679.22%. Given Cybin's stronger consensus rating and higher possible upside, equities research analysts clearly believe Cybin is more favorable than PDS Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Summary

Cybin beats PDS Biotechnology on 7 of the 13 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$64.53M	$3.35B	$6.33B	$12.33B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-1.73	18.89	20.88	25.51
Price / Sales	N/A	279.14	520.50	73.06
Price / Cash	N/A	125.35	43.18	55.00
Price / Book	16.50	6.90	10.01	7.03
Net Income	-$34.50M	$24.18M	$3.54B	$334.92M
7 Day Performance	-19.23%	0.77%	0.38%	-0.40%
1 Month Performance	-13.81%	-0.38%	-0.02%	1.07%
1 Year Performance	-26.90%	63.37%	35.07%	34.65%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	3.4091 of 5 stars	$1.15 +11.2%	$9.00 +686.0%	-36.8%	$63.91M	N/A	N/A	20	Analyst Revision
EDIT Editas Medicine	3.4716 of 5 stars	$2.48 -2.2%	$5.40 +118.2%	+58.5%	$240.37M	$40.52M	N/A	230
ALEC Alector	3.0568 of 5 stars	$2.07 -2.4%	$3.63 +75.1%	+54.7%	$227.61M	$21.05M	N/A	270
CHRS Coherus Oncology	3.1338 of 5 stars	$1.49 -0.3%	$8.67 +483.6%	+85.0%	$225.98M	$46.88M	0.88	330
CNTN Hillstream Biopharma	0.6161 of 5 stars	$3.16 -3.0%	N/A	N/A	$221.63M	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. EDIT, ALEC, CHRS, CNTN, and HELP

How does PDS Biotechnology compare to Editas Medicine?

Summary

How does PDS Biotechnology compare to Alector?

Summary

How does PDS Biotechnology compare to Coherus Oncology?

Summary

How does PDS Biotechnology compare to Hillstream Biopharma?

Summary

How does PDS Biotechnology compare to Cybin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. EDIT, ALEC, CHRS, CNTN, and HELP

How does PDS Biotechnology compare to Editas Medicine?

Do institutionals & insiders hold more shares of EDIT or PDSB?

Which has better earnings and valuation, EDIT or PDSB?

Does the media favor EDIT or PDSB?

Is EDIT or PDSB more profitable?

Do analysts rate EDIT or PDSB?

Which has more risk and volatility, EDIT or PDSB?

Summary

How does PDS Biotechnology compare to Alector?

Do analysts recommend ALEC or PDSB?

Does the media favor ALEC or PDSB?

Which has more risk & volatility, ALEC or PDSB?

Is ALEC or PDSB more profitable?

Which has higher valuation and earnings, ALEC or PDSB?

Do institutionals and insiders hold more shares of ALEC or PDSB?

Summary

How does PDS Biotechnology compare to Coherus Oncology?

Which has stronger earnings & valuation, PDSB or CHRS?

Do analysts rate PDSB or CHRS?

Does the media refer more to PDSB or CHRS?

Which has more risk and volatility, PDSB or CHRS?

Is PDSB or CHRS more profitable?

Do institutionals & insiders hold more shares of PDSB or CHRS?

Summary

How does PDS Biotechnology compare to Hillstream Biopharma?

Do institutionals and insiders believe in PDSB or CNTN?

Which has more risk and volatility, PDSB or CNTN?

Is PDSB or CNTN more profitable?

Which has better valuation & earnings, PDSB or CNTN?

Do analysts prefer PDSB or CNTN?

Does the media favor PDSB or CNTN?

Summary

How does PDS Biotechnology compare to Cybin?

Does the media refer more to HELP or PDSB?

Do insiders & institutionals have more ownership in HELP or PDSB?

Which has more volatility and risk, HELP or PDSB?

Is HELP or PDSB more profitable?

Do analysts recommend HELP or PDSB?

Which has stronger earnings and valuation, HELP or PDSB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools